Table 1.
Pathway Analysis of Genes Co-expressed with PDGFRB in CRC.
| P Value, Snoeren et al. | P Value, Smith et al. | P Value, Jorissen et al. | P Value, Combined | |
| KEGG pathway | ||||
| ECM-receptor interaction | 4.20E-12 | 3.90E-32 | 8.10E-15 | 3.33E-50 |
| Focal adhesion | 2.20E-10 | 5.70E-24 | 5.40E-11 | 1.42E-37 |
| Malaria | 7.90E-05 | 3.30E-15 | 5.40E-08 | 3.07E-23 |
| Complement and coagulation cascades | 1.30E-04 | 1.50E-08 | 7.10E-06 | 3.56E-15 |
| Glycosaminoglycan biosynthesis | 2.00E-02 | 2.80E-09 | 6.40E-06 | 2.97E-14 |
| Amebiasis | 7.50E-05 | 1.10E-10 | 1.30E-03 | 1.08E-13 |
| Phagosome | 1.00E-02 | 1.00E-08 | 1.20E-04 | 1.76E-12 |
| Leukocyte transendothelial migration | 2.00E-02 | 1.50E-06 | 1.90E-05 | 1.47E-11 |
| Cell adhesion molecules | 4.00E-02 | 1.10E-04 | 1.50E-03 | 1.25E-07 |
| Regulation of actin cytoskeleton | 3.00E-02 | 1.10E-04 | 7.30E-03 | 7.23E-07 |
| Vascular smooth muscle contraction | 2.00E-03 | 5.40E-03 | 2.00E-02 | 1.54E-05 |
| TGFB signaling pathway | 4.40E-05 | 4.60E-03 | 7.00E-02 | 1.95E-05 |
| GO pathway | ||||
| ECM | 8.9E-44 | 1.4E-98 | 6.8E-27 | 5.2E-135 |
| PDGF binding | 2.7E-22 | 2.3E-18 | 4.5E-8 | 2.7E-34 |
| Platelet activation | 7.2E-9 | 5.1E-10 | 1.2E-9 | 1.9E-23 |
| Platelet alpha-granule | 2.2E-6 | 3.7E-13 | 1.2E-6 | 7.2E-21 |
| Platelet degranulation | 2.9E-3 | 3.8E-10 | 2.4E-9 | 1.2E-19 |
| TGFB signaling pathway | 4.4E-6 | 4.1E-4 | 1.7E-7 |
PDGFRB-associated genes in each separate tumor cohortwere analyzed for overrepresentation ofKEGGpathways andGOterms by using R2. All KEGGpathways significantly associatedwith PDGFRB expression in at least two of three data sets are shown. A limited set of GO terms that are related to those KEGG pathways is shown in addition. Combined P values were calculated with the Web-based MetaP software.